KNSA Stock Analysis
KN
Uncovered
Kiniksa Pharmaceuticals Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The firm is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s portfolio of assets includes ARCALYST (rilonacept), Mavrilimumab, Vixarelimab and KPL-404. The firm's ARCALYST is an interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for treatment of recurrent pericarditis (RP), cryopyrin-associated periodic syndromes (CAPS), including familial cold auto-inflammatory syndrome (FCAS), and muckle-wells syndrome (MWS) in adults and children. Its Mavrilimumab is a monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα). Its Vixarelimab is a monoclonal antibody inhibitor of signaling through oncostatin M receptor beta (OSMRβ). Its KPL-404 is a monoclonal antibody inhibitor of CD40-CD154 interaction.